March 1, 2018
March 1, 2018
Curasight have received US patent notification with issue date 6 February 2018 and patent number 9884131, please see attached.
Curasight have provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
This is a major milestone for the further development of uTRACE® and of major strategic importance for Curasight’s strategy into the US-market.